Navigation Links
Generex Provides Update on Spinout of Antigen Express
Date:9/15/2011

WORCESTER, Mass. and TORONTO, Sept. 15, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.

"We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout," stated Mark Fletcher, Generex President & Chief Executive Officer.  "We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an  initial fund raising.  If the merger and the initial fund raising are successful, we will then seek a listing of the merged company's stock on a national stock exchange."

Generex will provide further updates as the transactions progress.

Mr. Fletcher has previously stated regarding the spinout:  "The transformation of Antigen Express into a separate, publicly traded entity is the centerpiece of the Generex strategic development plan.  For too long, Antigen Express and its promising immunotherapeutic vaccine technologies have been overshadowed by the Generex buccal drug delivery platform technologies.  We believe this spinout will help to unlock the true value of this dynamic company for our stockholders as it creates a pure play in immunotherapeutic vaccines for which we have already received an appraisal o
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... Calif. , May 23, 2013 Virobay, ... treatment for pain has reached an important milestone, as ... of VBY-036 - a selective cathepsin S inhibitor.   ... is a double-blind, randomized, placebo-controlled study designed to evaluate ... of VBY-036 in healthy adults. "The initiation ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
... ... Precision and Reduce Risk of False Positives/Negatives , ... Rochester, NY (PRWEB) September 16, 2009 -- iCardiac Technologies, ... that a top 15 pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
... ST. LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... on Monday, September 21st at 8:30 AM Eastern Daylight Time in ... over the Internet available at http://investor.sigmaaldrich.com/ . Users ... , About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
(Date:5/23/2013)... prostate cancer patients unnecessarily undergo surgery or harsh ... between slow-growing and aggressive forms of the disease. ... Hopkins Medical Institutes are developing technology that allows ... for relatively mild treatments or take drastic measures. ... Madabhushi, an associate professor of biomedical engineering at ...
(Date:5/23/2013)... in Neuron , the team reveal the interplay ... work funded by the Wellcome Trust and BBSRC. ... stimuli we improve our perceptual abilities. While these changes ... can also affect the fidelity of that response. ... Neuroscience explains: "When you communicate with others, you can ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... Researchers at the La Jolla Institute for Allergy & Immunology ... -- the specific immune system T cells which trigger the ... finding is an important advance that verifies in humans several ... key focal point for interrupting the disease process. "This ...
... Chris Austin recently discovered two new species of frogs in ... known vertebrate, averaging only 7.7 millimeters in size less ... , an Indonesian fish averaging more than 8 millimeters, from ... United States including LSU graduate student Eric Rittmeyer, made the ...
... new information on one of the most critical protein ... team of researchers with the U.S. Department of Energy,s ... of California (UC) Berkeley. The researchers have provided the ... by the protein machines known as proteasomes to identify ...
Cached Biology News:La Jolla Institute researchers identify pivotal immune cell in Type 1 diabetes in humans 2La Jolla Institute researchers identify pivotal immune cell in Type 1 diabetes in humans 3LSU professor discovers world's tiniest vertebrate 2New information on the waste-disposal units of living cells 2New information on the waste-disposal units of living cells 3
Request Info...
MAb to Mouse MHC Class I H-2Kd...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems ... Receive royalties for your hard work and ... us build it up,and market it internationally. ...
Biology Products: